Arrakis Therapeutics
http://arrakistx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arrakis Therapeutics
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
Roche Inks RNA-Targeted Small Molecule Pact With Ribometrix
Deal snapshot: Roche’s third partnership around small molecule, RNA-targeted therapies taps Ribometrix’s three-dimensional structural analysis of RNA to find pockets amenable to small molecule drugs.
Finance Watch: Biopharma VC Deals On Track For A Record-Breaking Year
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Lessons From Biotech Entrepreneurs: Pitching Your First-In-Class Innovation
The role of biopharma start-ups in bringing innovative therapies to the market has grown enormously. These waves of new specialist companies often have the most innovative approaches to targeting a disease, and big pharma has become increasingly reliant on their fresh ideas to power pipelines.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools